Loading
NB
NGM Biopharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by COLUMN GROUP L P, was filed 17 Nov 2023.
NGM Biopharmaceuticals Inc: what insiders have been doing
NGM Biopharmaceuticals Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of NGM Biopharmaceuticals Inc in twelve months, the latest record being from 8 April 2024.
Since 2019, the database holds 220 purchases and 46 sales by insiders of the company.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
498
Thresholds
n/a
Buy Volume
€153M
220 ops. · all time
Sell Volume
€11M
46 ops. · all time
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$3.8M
Net income-US$122.6M-3223.3% margin
Last declaration on 8 April 2024
Declarations498 total
2,650,177 sharesCommon StockSEC:0000950142-24-001001:1
90,442 sharesCommon StockSEC:0000950142-24-001001:2
11,103,333 sharesCommon StockSEC:0000950142-24-001001:3
858,035 sharesCommon StockSEC:0000950142-24-001001:4
968,990 sharesCommon StockSEC:0000950142-24-001001:5
2,265,758 sharesCommon StockSEC:0000950142-24-001001:6
1,298,908 sharesCommon StockSEC:0000950142-24-001001:7
1,298,908 sharesCommon StockSEC:0000950142-24-001001:8
100,000 sharesCommon StockSEC:0000950142-24-001001:9
100,000 sharesCommon StockSEC:0000950142-24-001001:10
15,000 sharesCommon StockSEC:0000950142-24-001001:11
44,000 sharesCommon StockSEC:0000950142-24-001001:12
1,000 sharesCommon StockSEC:0000950142-24-001001:13
2,650,177 sharesCommon StockSEC:0000950142-24-001000:1
90,442 sharesCommon StockSEC:0000950142-24-001000:2
11,103,333 sharesCommon StockSEC:0000950142-24-001000:3
858,035 sharesCommon StockSEC:0000950142-24-001000:4
968,990 sharesCommon StockSEC:0000950142-24-001000:5
2,265,758 sharesCommon StockSEC:0000950142-24-001000:6
1,298,908 sharesCommon StockSEC:0000950142-24-001000:7
1,298,908 sharesCommon StockSEC:0000950142-24-001000:8
100,000 sharesCommon StockSEC:0000950142-24-001000:9
100,000 sharesCommon StockSEC:0000950142-24-001000:10
15,000 sharesCommon StockSEC:0000950142-24-001000:11
44,000 sharesCommon StockSEC:0000950142-24-001000:12
25 of 498 declarations
About NGM Biopharmaceuticals Inc
NGM Biopharmaceuticals, Inc. is a U.S.-based biopharmaceutical company that was historically listed on the NASDAQ market in the United States. For international investors, the key point is that NGM has been a research-driven biotech platform rather than a commercial-stage pharma company: its business model has centered on discovering proprietary drug candidates and advancing them through early and mid-stage clinical development, often with a strong emphasis on partnering, portfolio prioritization, and targeted capital allocation. The company was incorporated in Delaware in December 2007 and commenced operations in 2008. Its headquarters are in South San Francisco, California, placing it in one of the most important biopharma clusters in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1426332/000162828023005569/ngm-20221231.htm?utm_source=openai))
NGM’s strategy has been described as “biology-centric,” meaning it uses a deep understanding of disease biology and protein engineering to generate differentiated therapeutic candidates. Over time, the company built a pipeline spanning several therapeutic areas, including liver and metabolic diseases, rare diseases, oncology, and ophthalmology. Its best-known clinical programs include aldafermin, an engineered FGF19 analog being developed for primary sclerosing cholangitis (PSC); NGM120, a GFRAL antagonist studied in hyperemesis gravidarum and cancer cachexia; and NGM707, an immuno-oncology antibody program targeting ILT2/ILT4 in advanced solid tumors. Earlier company disclosures also referenced additional assets such as NGM621 and NGM936. ([news.ngmbio.com](https://news.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-new-clinical-data-ongoing-trial-ngm707/?utm_source=openai))
Read moreShow less
From a competitive standpoint, NGM has operated as a small-cap biotech in a highly competitive, high-risk segment where scientific differentiation is essential but clinical execution and funding discipline are equally critical. Its competitive edge historically came from its internal discovery engine and its ability to originate wholly owned programs rather than relying solely on external in-licensing. At the same time, like many biotech peers, the company faced the typical constraints of a capital-intensive R&D model, where portfolio focus and partnership decisions materially shape long-term value creation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1426332/000162828023005569/ngm-20221231.htm?utm_source=openai))
A crucial current-market context for investors is that NGM is no longer an actively traded NASDAQ-listed stock. In April 2024, the company announced the closing of its tender offer / take-private transaction, after which its common shares ceased trading on Nasdaq and the company intended to be delisted and deregistered. In other words, while NGM is historically associated with the NASDAQ market in the United States, it is now a private company rather than a public listing. ([news.ngmbio.com](https://news.ngmbio.com/node/10536/pdf?utm_source=openai))
Geographically, NGM’s footprint has remained overwhelmingly U.S.-centric, with headquarters and core operations in South San Francisco. In 2025, the company continued to signal a narrower strategic focus, including a new Chief Medical Officer appointment to support the clinical development of its lead remaining programs, especially aldafermin for PSC and NGM120 for hyperemesis gravidarum and cachexia. That strategic reset suggests a company aiming to preserve optionality around a smaller number of higher-priority clinical assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1426332/000162828024010232/ngm-20231231.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
